Assessment Of The Impact Of Obesity On Sustained Virologic Response To Sofosbuvir Based Regimens In Chronic Hepatitis C Patients.

Abstract

ore than 170 million people are chronically infected with the hepatitis C virus (HCV) worldwide, thus HCV has become the main cause of chronic liver disease leading death from liver failure or hepatocellular carcinoma HCC in many countries. Viral eradication resulting from antiviral treatment has led to a decrease in these complications. However, treatment with pegylated interferon and ribavirin, which has been the standard-of-care therapy for chronic hepatitis C for the last decade, has been able to cure only about 40%-50% . Several factors, both viral and host mediated, have been shown to be partially responsible for the failure rate to antiviral treatment, these factors included obesity. In the current era of highly effective direct-acting antivi¬ral therapies for chronic HCV infection, estimation of factors that affect response to these drugs is still a critical issue despite of high efficacy of these drugs. The aim of our study is the assessment of the impact of obesity on SVR to sofosbuvir based regimens in CHC patients. This study included 200 chronic hepatitis C patients eligible for antiviral therapy according to the Egyptian guidelines issued by the National Committee for Control of Viral Hepatitis.The patients were divided into 2 groups each group included 100 patients,